NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
Author: Tamas Sohajda
Cyclolab R&D Director
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
Happy 70th Birthday, Lajos!
CycloLab celebrates birthday of L. Szente (70), former CEO Lajos Szente has been contributing to the development of the global
Clinical trial for Postprandial Responses to ACD-encapsulated Hydroxytyrosol-enriched Bread
The amelioration of postprandial glucose and insulin responses to bread is of great importance since it may have significant beneficial
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,
Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs
Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development
Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it
Top-line final data from CD-enabled Cantrixil Phase I study confirms prior positive efficacy and safety signals
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin